Monocyte Count/HDL Cholesterol Ratio and Cardiovascular Disease in Patients With Obstructive Sleep Apnea Syndrome: A Multicenter Study

dc.authorid0000-0002-7094-837X
dc.contributor.authorKoseoglu, Handan Inonu
dc.contributor.authorPazarli, Ahmet Cemal
dc.contributor.authorKanbay, Asiye
dc.contributor.authorDemir, Osman
dc.date.accessioned2025-05-10T19:41:30Z
dc.date.issued2018
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground: Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for cardiovascular disease (CVD). Although monocyte to high-density lipoprotein cholesterol ratio (MHR) is increasingly being implicated in cardiovascular morbidity and mortality, no study has attempted to determine the role of MHR in cardiovascular morbidity of patients with OSAS. We aimed to investigate the association between MHR and CVD in patients with OSAS and the relationship between severity of OSAS, polysomnographic parameters, and MHR. Methods: In this cohort study, patients who had undergone a full-night polysomnography for the diagnosis of OSAS were recruited. Included patients were grouped according to the apnea-hypopnea index (AHI) as mild (5-15), moderate (15-30), and severe (>30) OSAS. Patients with AHI < 5 served as the control group. The presence of heart failure, coronary artery disease, or arrhythmia was defined as CVD. Results: A total of 1050 patients were included (131 controls, 222 mild, 228 moderate, and 469 severe OSAS). The severe group had higher MHR compared with the control and other OSAS groups (9.99, 12.11, 13.65, and 20.67 in control, mild, moderate, and severe OSAS groups, respectively, P < .001). The MHRs were significantly correlated with AHI, oxygen desaturation index, and minimum O-2 saturation values (P < .001). Values of MHR were significantly higher in patients with CVD compared with those without (P < .001). Multiple regression analysis demonstrated that MHR is an independent predictor of CVD. Conclusion: The MHR is strongly associated with CVD and the severity of OSAS and might be used as a biomarker to predict CVD in patients with OSAS.
dc.identifier.doi10.1177/1076029616677803
dc.identifier.endpage144
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue1
dc.identifier.pmid27837155
dc.identifier.scopusqualityQ2
dc.identifier.startpage139
dc.identifier.urihttps://doi.org/10.1177/1076029616677803
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10356
dc.identifier.volume24
dc.identifier.wosWOS:000417681500018
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofClinical and Applied Thrombosis-Hemostasis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectmonocyte
dc.subjectHDL cholesterol ratio
dc.subjectcardiovascular disease
dc.subjectobstructive sleep apnea syndrome
dc.subjectmonocyte
dc.subjectHDL cholesterol
dc.titleMonocyte Count/HDL Cholesterol Ratio and Cardiovascular Disease in Patients With Obstructive Sleep Apnea Syndrome: A Multicenter Study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10356.pdf
Boyut:
232.78 KB
Biçim:
Adobe Portable Document Format